12:00 AM
Nov 10, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MRX-4: Phase II data

Top-line data from a double-blind, South African Phase II trial in 105 patients with allergic rhinitis showed that MRX-4 significantly reduced a composite of 6 rhinitis symptoms (rhinorrhea, nasal itching, sneezing,...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >